All posts by medical

Carmell Therapeutics Announces Appointment of Dr. Israel Nur as Scientific Advisor – Business Wire

PITTSBURGH--(BUSINESS WIRE)--Carmell Therapeutics, a pioneering company in the development and commercialization of innovative Plasma-based Bioactive Materials (PBMs) to accelerate bone and soft tissue healing, today announced that Dr. Israel Nur joined the company as a Scientific Advisor. Carmell Therapeutics has a unique biologic solution that addresses unmet needs in bone and soft tissue treatment and utilizes an innovative, proprietary platform that accelerates healing, reduces complications and enables patients to get back to their daily lives more quickly.

Israel brings a wealth of plasma derivatives experience and will provide invaluable guidance to Carmell as we continue to expand, which we are doing across the board, in fact, weve already doubled our footprint in Pittsburgh, said Randy Hubbell, President and Chief Executive at Carmell Therapeutics. We are thrilled to welcome Israel at this pivotal time for the organization as we advance our efforts to bring CT-101 Bone Healing Accelerant (BHA) to patients and healthcare providers.

Earlier this year, Carmell received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for its BHA, which will help expedite the companys lead program to the goal of a Biologic License Application (BLA) approval.

Im looking forward to working with Carmell at this exciting time and sharing my expertise in biologic development of plasma-based materials, said Dr. Israel Nur. Bone Healing Acceleration is an important area that could make a considerable impact in the orthopedic/wound healing market and Carmell has the unique, transformational technology to make this a reality.

Dr. Israel Nur has over four decades of research and development (R&D) in biological experience, with a strong focus in plasma and serum derived product industry, in both the public and private sectors. He has proven expertise in developing biosurgical combination products. Most recently, Israel Nur was a senior director at Ethicon, leading the Manufacturing Scientific Team. Before that, he was managing the Ethicon Biosurgery R&D research and innovation team. Prior to the acquisition of Omrix biopharmaceuticals Inc. by JNJ, Dr. Nur was VP, R&D and one of the founders of Omrix. He also developed a line of plasma derived products, including the Intravenous immunoglobulin (OmriGam). During the early 2000s, under his leadership and with the collaboration of the Centers for Disease Control and Prevention (CDC), National Institutes of Health (NIH), Israel Defense Forces (IDF), the US Army and the Ministry of Defense, Omrix developed and manufactured a line of biodefense and bioterrorism products. Before joining the industry, Dr. Nur was a Visiting Fellow, Laboratory of Biochemical Pharmacology, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NIH, in Bethesda, Maryland. He started his career in NIH as a research fellow in National Institute of Allergy and Infectious Diseases (NIAID) in Fort Dietrich, Frederick MD.

Dr. Nur is an author of 53 publications in peer review journals and an inventor of more than 40 patents. He earned a Doctor of Philosophy in Biochemistry and a Master of Science in Microbiology from The Hebrew University of Jerusalem in Israel.

About Carmells PBM Technology Platform

Carmell Therapeutics unique PBM technology platform can be delivered in multiple formats to the site of injury from putties to pastes to surgical screws. A proprietary manufacturing process ensures product safety and that bioactive regenerative factors are delivered as the product degrades allowing for optimal healing. Carmell currently has two PBM products in development a Bone Healing Accelerant and a Tissue Healing Accelerant.

About Carmell Therapeutics

Carmell Therapeutics (Carmell) is addressing the burden of bone and tissue healing with its proprietary Plasma-based Bioactive Material (PBM) technology, designed to improve patient outcomes and reduce health care costs. Carmells transformational biologic will have significant impact on important therapeutic areas with many unmet clinical needs such as trauma fixation healing, spine fusion, sports medicine, dental bone regrowth, wound care, aesthetic medicine and animal health. For more information, please visit http://www.carmellrx.com.

Read this article:
Carmell Therapeutics Announces Appointment of Dr. Israel Nur as Scientific Advisor - Business Wire

Endocannabinoids in the body can help fight intestinal infections – News-Medical.Net

Reviewed by Emily Henderson, B.Sc.Oct 7 2020

Endocannabinoids, signaling molecules produced in the body that share features with chemicals found in marijuana, can shut down genes needed for some pathogenic intestinal bacteria to colonize, multiply, and cause disease, new research led by UT Southwestern scientists shows.

The findings, published online today in Cell, could help explain why the cannabis plant - the most potent part of which is marijuana - can lessen the symptoms of various bowel conditions and may eventually lead to new ways to fight gastrointestinal infections.

Discovered in 1992, endocannabinoids are lipid-based neurotransmitters that play a variety of roles in the body, including regulating immunity, appetite, and mood. Cannabis and its derivatives have long been used to relieve chronic gastrointestinal conditions, including irritable bowel syndrome and inflammatory bowel disease. Studies have shown that dysregulation of the body's endocannabinoid system can lead to intestinal inflammation and affect the makeup of gut microbiota, the population of different bacterial species that inhabit the digestive tract.

However, study leader Vanessa Sperandio, Ph.D., professor of microbiology and biochemistry at UTSW, says it's been unknown whether endocannabinoids affect susceptibility to pathogenic gastrointestinal infections.

To help answer this question, Sperandio and her colleagues worked with mice genetically altered to overproduce the potent mammalian endocannabinoid 2-arachidonoyl glycerol (2-AG) in various organs, including the intestines. When the researchers infected these animals and their unmodified littermates with Citrobacter rodentium, a bacterial pathogen that attacks the colon and causes marked inflammation and diarrhea, the mutant mice developed only mild symptoms compared with the more extreme gastrointestinal distress exhibited by their littermates.

Examination of the mutant animals' colons showed far lower inflammation and signs of infection. These mice also had significantly lower fecal loads of C. rodentium bacteria and cleared their infection days faster than their unmodified littermates. Treating genetically unmodified animals with a drug that raised levels of 2-AG in the intestines produced similar positive effects.

Sperandio's team found that increased levels of 2-AG could also attenuate Salmonella typhimurium infections in mice and impede enterohemorrhagic Escherichia coli - a particularly dangerous gastrointestinal bacteria that infects humans - in order to express the virulence traits needed for a successful infection.

Conversely, when the researchers treated mammalian cells in petri dishes with tetrahydrolipstatin, a Food and Drug Administration-approved compound sold commercially as Alli that inhibits 2-AG production, they became more susceptible to the bacterial pathogens.

Further experiments showed that 2-AG exerted these effects on C. rodentium, S. typhimurium, and E. coli by blocking a bacterial receptor known as QseC. When this receptor senses the host signaling molecules epinephrine and norepinephrine, it triggers a molecular cascade necessary to establish infection. Plugging this receptor with 2-AG prevents this virulence program from activating, Sperandio explains, helping to protect against infection.

Sperandio notes that these findings could help explain some of the effects of cannabis use on inflammatory bowel conditions. Although studies have shown that cannabis can lower inflammation, recent research has shown that these conditions also tend to have a bacterial component that might be positively affected by plant cannabinoids.

In addition, cannabis compounds or synthetic derivatives could eventually help patients kick intestinal bacterial infections without antibiotics. This could be particularly useful for infections caused by enterohemorrhagic Escherichia coli, Sperandio says, which produces a deadly toxin when it's treated with antibiotics, rendering these drugs not only counterproductive but extremely dangerous. Because many virulent bacteria that colonize areas elsewhere in the body also have the QseC receptor, she adds, this strategy could be used more broadly to fight a variety of infections.

By harnessing the power of natural compounds produced in the body and in plants, we may eventually treat infections in a whole new way."

Vanessa Sperandio, Ph.D., professor of microbiology and biochemistry at UTSW

Read the rest here:
Endocannabinoids in the body can help fight intestinal infections - News-Medical.Net

Crop Biotechnology, physiology and translational genomics to feed and fuel the world – Newswise

Newswise October 6, 2020 Accelerated crop improvement is needed to meet both global population growth and climate change generated stresses on crops. TheCrop Biotechnology, physiology and translational genomics to feed and fuel the worldsymposium at theTranslating Visionary Science to Practice ASA, CSSA, SSSA International Annual Meetingwill address these topics.

The meeting is being held virtually, Nov. 9-13, 2020 and is hosted by the American Society of Agronomy, Crop Science Society of America and Soil Science Society of America. Media are invited; preregistration is required.

The presentations are:

Presentations may be watched asynchronously, and there will be a scheduled Q&A time to speak with presenters during the meeting. Presentations will be available for online viewing for 90 days after the meeting for all registrants. For more information about theTranslating Visionary Science to Practice 2020meeting,visithttps://www.acsmeetings.org/.

Media are invited to attend the conference. Pre-registration by Nov. 2, 2020 is required. Visithttps://www.acsmeetings.org/mediafor registration information.

To speak with one of the scientists, contact Susan V. Fisk, 608-273-8091,sfisk@sciencesocieties.orgto arrange an interview.

Excerpt from:
Crop Biotechnology, physiology and translational genomics to feed and fuel the world - Newswise

NIH intramural researcher Dr. Harvey Alter wins 2020 Nobel Prize in Physiology or Medicine – National Institutes of Health

News Release

Monday, October 5, 2020

National Institutes of Health intramural researcher Harvey J. Alter, M.D., has won the 2020 Nobel Prize in Physiology or Medicine for his contributions to the discovery of the hepatitis C virus. Dr. Alter is a Senior Scholar at the NIH Clinical Centers Department of Transfusion Medicine and shares the award with Michael Houghton, Ph.D., University of Alberta, Canada, and Charles M. Rice, Ph.D., Rockefeller University, New York City.

The Royal Swedish Academy of Sciences said, Prior to their work, the discovery of the Hepatitis A and B viruses had been critical steps forward, but the majority of blood-borne hepatitis cases remained unexplained. The discovery of Hepatitis C virus revealed the cause of the remaining cases of chronic hepatitis and made possible blood tests and new medicines that have saved millions of lives.

I am overwhelmed at the moment, but so pleased that this originally obscure virus has proven to have such a large global impact, said Dr. Alter. There are so many persons at NIH who advanced my research, but for now I can only thank NIH, itself, for creating the permissive and collaborative environment that supported these studies over the course of decades. I dont believe my contributions could have occurred anywhere else.

Dr. Alters career at NIH has spanned more than 50 years where he focused his research on the occurrence of hepatitis in patients who had received blood transfusions. In the 1970s, despite the discovery of hepatitis B, Dr. Alter saw a significant number of patients receiving blood transfusions still developed chronic hepatitis due to an unknown infectious agent. Dr. Alter and his colleagues showed that blood from these hepatitis patients could transmit the disease to chimpanzees, the only susceptible host besides humans. Subsequent studies also demonstrated that the unknown infectious agent had the characteristics of a virus. Alters methodical investigations defined a new, distinct form of chronic viral hepatitis, which became known as non-A, non-B hepatitis. His work was instrumental in leading to the development of new diagnostic and therapeutic agents and providing the scientific basis for instituting blood donor screening programs that have decreased the incidence of transfusion-transmitted hepatitis to near zero.

Harvey Alter is a scientists scientist smart, creative, dedicated, persistent, self-effacing, intensely dedicated to saving lives, said NIH Director Francis S. Collins, M.D., Ph.D. His work to identify the nature of the hepatitis C virus has led to dramatic advances in protecting the blood supply from this very serious illness, and ultimately to the development of highly successful therapy.

Dr. Alter had focused on viral hepatitis even before his work on hepatitis C. In the 1960s, he co-discovered the Australia antigen, a key to detecting hepatitis B virus. Later, he spearheaded a project at the NIH Clinical Center that created a storehouse of blood samples used to uncover the causes and reduce the risk of transfusion-associated hepatitis. In 2000, Alter was awarded the prestigious Clinical Lasker Award. In 2002, he became the first NIH Clinical Center scientist elected to the National Academy of Sciences, and in that same year he was elected to the Institute of Medicine. In 2013, Dr. Alter was honored with the distinguished Canada Gairdner International Award.

Harvey is known for a very sharp sense of humor, a tireless, work ethic, and for treating everyone well, said James K. Gilman, M.D., chief executive officer of the NIH Clinical Center. As a long-time military physician, I am grateful to what Harvey and his co-winners have done to make it possible to provide a safe blood supply to the men and women who serve the country in uniform.

Dr. Alters co-recipient Dr. Rice has received continuous NIH funding totaling more than $67 million since 1987, primarily from NIHs National Institute of Allergy and Infectious Diseases.

For more on Drs. Alter, Houghton and Rices contributions to the discovery of the hepatitis C virus, visit the Royal Swedish Academy of Sciences site: https://www.nobelprize.org/prizes/medicine/2020/press-release/.

About the NIH Clinical Center: The NIH Clinical Center is the worlds largest hospital entirely devoted to clinical research. It is a national resource that makes it possible to rapidly translate scientific observations and laboratory discoveries into new approaches for diagnosing, treating, and preventing disease. Over 1,600 clinical research studies are conducted at the NIH Clinical Center, including those focused on cancer, infectious diseases, blood disorders, heart disease, lung disease, alcoholism and drug abuse. For more information about the Clinical Center, visit https://clinicalcenter.nih.gov/index.html.

About the National Institutes of Health (NIH):NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.nih.gov.

NIHTurning Discovery Into Health

###

More:
NIH intramural researcher Dr. Harvey Alter wins 2020 Nobel Prize in Physiology or Medicine - National Institutes of Health

Synthace Announces the Launch of New Product Helping Scientists Execute and Scale Key Assays – BioSpace

Oct. 7, 2020 08:00 UTC

BOSTON & LONDON--(BUSINESS WIRE)-- Synthace Ltd, the company behind Antha, the cloud-based software platform for automating and improving the success rate of biological processes, has launched a new software capability for streamlining a fundamental workhorse of biochemistry: the enzyme-linked immunosorbent assay (ELISA). Antha now allows researchers to flexibly design and execute automated ELISA protocols and automatically gather, structure, and analyze the data in an accessible, in-depth format, saving researchers valuable time from design to data acquisition.

A Powerful Detection Tool

ELISA protocols are ubiquitous in life science research but feature prominently in drug discovery, pathology (plant and animal), medical diagnostics, and quality control. Essentially, ELISAs use specific antibodies, like those generated by our immune system, to detect antigens and give off a detectable signal using an enzyme such as horseradish peroxidase. Without these assays, scientists would not be able to rapidly identify viral proteins, like in the HIV test, or detect potential allergens or toxins in food. An ELISA test for coronavirus was one of the first antibody detection methods available at the outset of the pandemic.

Shifting Bottlenecks and Reducing Burdens

ELISA protocols have repetitive liquid handling steps that lend themselves easily to automation. These complex protocols are often performed on multiple pieces of equipment that are not always physically connected. This creates several barriers: the scientist must know how to program all of the machines involved as well as acquire and process the data from them individually. Ultimately, automating ELISA assays reduces the time spent on liquid handling, but creates two new bottlenecks in programming and data handling.

To reduce the programming and data handling burdens for researchers, Synthaces Antha acts as a single point of contact to perform the assay and acquire results. Antha is device-agnostic, with an intuitive user interface that allows scientists to design a flexible, end-to-end protocol and test it step-by-step in silico before sending it to the machines involved.

Changing How We Gather Data

In addition to showing the user a preview of the experiment, Antha automatically gathers tracks and structures data generated during the assays, even from non-integrated devices. At the conclusion of the protocol, Antha will generate a complete data analysis and visualization of these data automatically, saving time and resources spent gathering data and formatting it manually.

Clients trialing the new ELISA feature in Antha reported:

ELISAs are a critical assay across many fields within life science. As highly sensitive assays, they require precision and reproducibility that automation can provide. Flexible end-to-end approaches for ELISAs help scale key assays across many sectors, including biopharmaceutical development.

This addition to our Antha platform will enable scientists to perform key assays reliably and reproducibly at scale. Most importantly, this will allow scientists to spend less time in the lab, enabling them to design better experiments, explore new insights, and ultimately increase the impact of their research, concluded Dr. Tim Fell, CEO of Synthace.

Join the Synthace team on Friday, 16th October at 3pm BST / 10am EDT for a live demo to learn more about Antha-powered ELISAs and to ask our experts about automation, Antha, and more!

To learn more about automating ELISA protocols and getting the most from your data, visit: https://www.synthace.com/our-protocols/elisa-detail/

Follow Synthace

Synthace Blog Join the Twitter Conversation Join us on LinkedIn

About Synthace

Based in London, UK, and Boston, the US, Synthace is accelerating biological discovery & optimization through computer-aided biology. Our cloud software platform, Antha, empowers biologists by enabling them to flexibly program their lab automation without the need to code. The graphical user interface has been designed by biologists for biologists, intuitively enabling them to automate their whole experiment from planning to execution, data collection, and analysis. Antha is the cornerstone of the lab of the future, seamlessly connecting the digital realm of data with the physical of lab automation and wet-lab biology, automatically collecting and structuring data to accelerate biological understanding.

Synthace is unlocking the potential of biology for humankind and our environment. Synthace works with biopharmaceutical companies, and in 2016 was recognized by the World Economic Forum as a Technology Pioneer that is helping shape the Fourth Industrial Revolution, and in 2018 as a cool vendor by Gartner.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201007005087/en/

Excerpt from:
Synthace Announces the Launch of New Product Helping Scientists Execute and Scale Key Assays - BioSpace

Rare genetic disease of the nervous and heart system discovered in children – Euro Weekly News

A rare genetic disease of the nervous and heart system has been discovered in children.

RESEARCHERS from Idibell and Hospital Sant Joan de Du in Barcelona have discovered a new severe rare genetic disease of metabolism that affects children and is characterised by problems in brain and heart development.

The gene that causes the disease, SHMT2, has been identified through the analysis of the genome of five patients -three Spanish, one French and one American.

The study of patients from overseas was made possible by the GeneMatcher platform, which connects clinicians and researchers from all over the world interested in the study of the same genes.

Children with SHMT2 deficiencies suffer from cognitive development problems, motor disorders and progressive heart disease that may even need transplantation.

To analyse the genome, the Idibell team developed sophisticated algorithms aimed at identifying the DNA changes in the genes most likely to cause disease.

The SHMT2 gene directs the production of an enzyme that controls the metabolism of folic acid and amino acids, essential elements to form proteins, with a key function in the development of the brain.

In the patients cells obtained through skin biopsy, the researchers have been able to determine the altered function by measuring the metabolites of the pathway in the biochemistry laboratory of the Hospital Sant Joan de Du (HSJD).

This discovery has been carried out by the team led by the geneticist and researcher Aurora Pujol.

Thanks to genomic medicine we can diagnose patients who have been unresponsive for many years, and better understand the mechanisms that govern essential biochemical reactions and the development of organs and tissues, she explained.

ngels Garca-Cazorla, a neuropediatrician who controls the three diagnosed patients and co-leader of the research, adds that Since these are known biochemical pathways, we are working on experimental treatments to supplement the deficient metabolites with the aim of improving the quality of life of the patients.

On the other hand, the team of researchers has also found alterations in the mitochondria, the organelles responsible for energy production and essential for most of the biochemical functions essential to life.

The study, published in the scientific journal Acta Neuropathologica and financed by funds from the Carlos III Health Institute, Ciberer and the project of undiagnosed neurological diseases of Catalonia, URD-Cat, identifies the gene that causes the disease, SHMT2, and opens the way to work on experimental treatments that will improve the lives of patients.

Thank you for reading this article Rare genetic disease of the nervous and heart system discovered in children.

Euro Weekly Newscontinues to bring you a range of News that doesnt cost you anything but your internet connection. Whether its Local Spanish News or International Entertainment News, weve got you covered!

Read the rest here:
Rare genetic disease of the nervous and heart system discovered in children - Euro Weekly News

Expert: How geotagged content is used in research – Newswise

Newswise BUFFALO, N.Y. In a recent commentary published in the journal Nature Human Behavior, University at Buffalo geographic information science expert Yingjie Hu and colleague Ruo-Qian Wang wrote about how Twitters decision to remove users ability to tag the precise locations of Tweets might affect research in disaster response, public health and other areas.

The authors concluded that the change may not have a pivotal impact on studies that rely on this kind of content, as a large proportion of precisely geotagged posts in three Twitter datasets they examined originated from third-party apps like Instagram (the datasets were originally collected for other studies examining peoples reaction to extreme weather events). The researchers also noted that Twitter still allows for less precise geotagging, enabling users to tag places such as a restaurant, a park, a city or a country, as opposed to a precise latitude and longitude.

Nevertheless, the recent change raises a number of issues that scientists must consider, Hu and Wang said in their Sept. 7 piece.

From a privacy protection perspective, Twitters decision reflects the concerns of society in general on privacy issues. Researchers should increase our awareness of the potential privacy and safety issues that may exist in our data and research practice and should follow relevant guidelines, such as those from institutional review boards (IRBs), to protect the privacy of individuals, according to Hu, PhD, an assistant professor of geography in the UB College of Arts and Sciences, and Wang, PhD, an assistant professor of civil and environmental engineering in the Rutgers University-New Brunswick School of Engineering, writing in Nature Human Behavior.

In an interview, Hu explained how geotagged social media content can enable valuable research.

After a major disaster, such as an earthquake or a hurricane, geotagged information can provide firsthand information about the situation on the ground, Hu said. Even before first responders arrive at those locations, information posted directly by the people from the disaster-affected area can inform disaster response.

Another application for geotagged content is in public health. From geotagged tweets, we can know what people are talking about and from which locations, and we can further identify the geographic areas where people are talking about flu, cough, or other health-related keywords. In political science, geotagged posts can provide some understanding of peoples political opinions in different geographic locations, or of how people are reacting to new government policies.

As scientists conduct this type of research, Hu believes its vital not only for researchers like himself to think about privacy and ways to safeguard data, but for app developers and corporations to do the same. One important step involves transparency. He argues that its important for companies to make it clear to users how their data may be used. And that goes for both social media platforms that allow people to geotag posts, and for apps that engage in location-tracking, he says.

I think it will be good if individuals can have more information and get a better understanding of how their data are collected, Hu said.

Ultimately, he added, If we can provide good privacy protection measures on location data, we can use those data for many applications that benefit our society, such as in disaster response, public health, transportation modeling and other areas.

Go here to see the original:
Expert: How geotagged content is used in research - Newswise

Gravyty Launches Gravyty Guard the First Data Security Solution Built to Protect Donor Data at Nonprofit Organizations – AiThority

Gravyty Expands AI Platform to Address Human-Layer Data Security Risks

Gravyty, the market-defining leader of artificial intelligence (AI) for Social Good, announced Gravyty Guard, the first data security technology focused on the human layer of security and specifically designed to protect the most sensitive donor data at nonprofit organizations from intentional and unintentional data breaches. The announcement comes in direct response to the worst year for nonprofit data security, with thousands of nonprofit organizations announcing data breaches and millions of donor data records compromised. Gravyty Guard protects nonprofit organizations and their well-intentioned employees from unintentional and malicious data breaches and provides the first solution to secure organizations most sensitive data.

Recommended AI News: HyperChain CEO Stelian Balta About Companys Plan To Extend Investments In DeFi Projects

Over the past six months, remote work has redefined how workforces access and share donor data, creating new and alarming security vulnerabilities for nonprofit organizations, particularly through well-intentioned employees who have authorized access to their organizations data. In fact,85%of data breaches occur as a result of inadvertent actions. As data sets grow exponentially and organizations become more data-driven, these vulnerabilities are only projected to get worse. The most prominent risks now become well-intentioned employees who make mistakes with their organizations data.

Nonprofit organizations find themselves in the crosshairs of being data-driven and needing to protect their most sensitive donor data. In the past, weve relied on policy to provide security assurances, but 2020 has proven that we need more, and it has to start at the most vulnerable level the human layer, explainedAdam Martel, co-founder and CEO, Gravyty. With Gravytys deep understanding of the nonprofit sector and human behavior in advancement, we realized that we could expand our AI platform so nonprofits can address the security challenge that will define this decade, protecting against fraud and data breaches with world-class technology.

Recommended AI News: VirBELA Announces Collaboration With HTC VIVE To Introduce VIVE Campus, Redefining The Next Normal

By understanding human behaviors unique to the nonprofit fundraising space, Gravyty uses advanced technologies to train models, deploy proactive alerts, and provide detailed, flexible reporting to protect employees from being the source maliciously or accidentally of the next donor data security breach. Known ashuman-layer security, the technologies behind Gravyty Guard proactively alert fundraisers to potential data breaches and provide steps to remediate data risks. These protections include threats such as:

Phishing, spear phishing, and other email infiltration attacks attempt to trick humans into scenarios that allow hackers to extract sensitive donor data through ransomware, trojan malware, and other methods. An estimated 135 million of these attacks are attempted every day. Historically focused on the for-profit sector, the nonprofit sector has only recently become a target for bad actors. Gravyty Guard is flexible, configuring to the specific needs of any organization to alert and protect fundraisers from these attacks.

Exfiltration happens when employees use email, text messages, messaging apps, thumb drives, cloud apps, and other vehicles to transfer data to places it should never be, without authorization. The most common data exfiltration occurs when an employee forwards a work email to their personal account.75%of IT leaders say employeesintentionallyput an organizations data at risk through exfiltration methods. Gravyty Guard allows nonprofit organizations to select compliance frameworks that apply to their business GDPR, CCPA, HIPAA, or otherwise and alerts managers when a fundraiser is about to create a vulnerability.

IT security is often highly effective at monitoring networks for abnormal traffic. However, we cant say the same about tracking abnormalities in human behavior. More than70%of people have mistakenly sent personally identifiable information (PII) or business-sensitive data to the wrong email recipient, creating a data breach. The source of these breaches could be as small as trusting auto-suggest to fill in an email address or a typo. Gravyty Guard uses AI to monitor security anomalies at the human-layer, alerting fundraisers when something doesnt line up about the data within their message and the recipients to whom its being sent.

The last 30 years in security have been defined by protecting networks and devices. Now, bad actors have turned their attention to new vulnerabilities an organizations employees, saidRich Palmer, co-founder and CTO, Gravyty. As the leader in AI technology for the nonprofit sector, addressing human-layer security is a natural progression for Gravyty because frontline fundraisers access sensitive donor data every day. Well empower nonprofit organizations to ensure their employees dont make mistakes that cause donor data breaches.

Recommended AI News: The Next Release Of SAS Viya Introduces A New Category Of Analytics For The Cloud

Follow this link:
Gravyty Launches Gravyty Guard the First Data Security Solution Built to Protect Donor Data at Nonprofit Organizations - AiThority

Journeys of Discovery: Grand Canyon murdera true story of redemption – KCBX

Correspondent Tom Wilmer visits withAnnette McGivney, author of "Pure Land: A True Story of Three Lives, Three Cultures, and the Search for Heaven on Earth." McGivney is Southwest Editor forBackpacker Magazineand former professor of journalism at Northern Arizona University.

McGivneys book tells the story of Tomomi Hanamure, a Japanese citizen who loved exploring the wilderness of the American Southwest. She was murdered on her birthdayMay 8, 2006. She was stabbed 29 times as she hiked to Havasu Falls on the Havasupai Indian Reservation at the bottom of the Grand Canyon. Her killer was a distressed 18-year-old Havasupai youth.

This show was originally broadcast July 31, 2018 and is reposted as a best-of-the-best podcast in celebration of Journeys of Discoverys 30th anniversary producing on-air and digital media podcasts featured on KCBX and NPR One.

"Pure Land" is about this tragedy. But it is also the story of how McGivneys quest to understand Hanamures life and death wound up guiding the author through her own life-threatening crisis.

On this journeystretching from the southern tip of Japan to the bottom of the Grand Canyon, and into the ugliest aspects of human behavior"Pure Land" offers proof of the healing powers of nature and the resiliency of the human spirit.

You are invited to subscribe to the Lowell Thomas Award-winning podcast travel show,Journeys of Discovery with Tom Wilmer,featured on theNPR Podcast Directory,Apple Podcast,theNPR One App&Stitcher.com.Twitter: TomCWilmer.Instagram: Thomas.Wilmer.Underwriting support provided byThe Society of St. Vincent de Paul,and Honolulu based, Hawaiian Legacy Reforestation Initiative.

Read the original here:
Journeys of Discovery: Grand Canyon murdera true story of redemption - KCBX

Europe is building a ‘digital twin’ of Earth to revolutionize climate forecasts – Science Magazine

At 1-kilometer resolution, a European climate model (left) is nearly indistinguishable from reality (right).

By Paul VoosenOct. 1, 2020 , 10:40 AM

The European Union is finalizing plans for an ambitious digital twin of planet Earth that would simulate the atmosphere, ocean, ice, and land with unrivaled precision, providing forecasts of floods, droughts, and fires from days to years in advance. Destination Earth, as the effort is called, wont stop there: It will also attempt to capture human behavior, enabling leaders to see the impacts of weather events and climate change on society and gauge the effects of different climate policies.

"Its a really bold mission, I like it a lot, says Ruby Leung, a climate scientist at the U.S. Department of Energys (DOEs) Pacific Northwest National Laboratory. By rendering the planets atmosphere in boxes only 1 kilometer across, a scale many times finer than existing climate models, Destination Earth can base its forecasts on far more detailed real-time data than ever before. The project, which will be described in detail in two workshops later this month, will start next year and run on one of the three supercomputers that Europe will deploy in Finland, Italy, and Spain.

Destination Earth rose out of the ashes of Extreme Earth, a proposal led by the European Centre for Medium-Range Weather Forecasts (ECMWF) for a billion-euro flagship research program. The European Union ultimately canceled the flagship program, but retained interest in the idea. Fears that Europe was falling behind China, Japan, and the United States in supercomputing led to the European High-Performance Computing Joint Undertaking, an 8 billion investment to lay the groundwork for eventual exascale machines capable of 1 billion billion calculations per second. The dormant Extreme Earth proposal offered a perfect use for such capacity. This blows a soul into your digital infrastructure, says Peter Bauer, ECMWFs deputy director of research, who coordinated Extreme Earth and has been advising the European Union on the new program.

Typical climate models run at resolutions of 50 or 100 kilometers; even top ones like ECMWFs European model run at 9 kilometers. The new models 1-kilometer resolution will enable it to directly render convection, the vertical transport of heat critical to the formation of clouds and storms, rather than relying on an algorithmic approximation. I call it the third dimension of climate modeling, says Bjorn Stevens, a climate scientist at the Max Planck Institute for Meteorology. The model will also simulate the ocean in fine enough detail to capture the behavior of swirling eddies that are important movers of heat and carbon.

In Japan, pioneering runs of a 1-kilometer global climate model have shown that directly simulating storms and eddies leads to better short-term rainfall predictions. But it should also improve climate forecasts over periods of months and years. Recent work has shown climate models are not capturing predictable changes in wind patterns that drive swings in regional temperature and rainfallprobably because the models fail to reproduce storms and eddies.

The high resolution will also enable Destination Earth to base its forecasts on more detailed data. Weather models suck in observations of temperature and pressure from satellites, weather stations, aircraft, and buoys to guide their simulations. But coarse grids mean the models cant assimilate measurements that dont average well or cover broad areas, such as fractures opening up in sea ice. Destination Earth will close this gap, says Sandrine Bony, a cloud scientist at the Pierre Simon Laplace Institute. The scales that are resolved are closer to the scales that are measured.

The model will also incorporate real-time data charting atmospheric pollution, crop growth, forest fires, and other phenomena known to affect weather and climate, says Francisco Doblas-Reyes, an earth system scientist at the Barcelona Supercomputing Center. If a volcano goes off tomorrow, thats important for the risk of tropical precipitation failure in a few months. And it will fold in data about society, such as energy use, traffic patterns, and human movements (traced by mobile phones).

The goal is to allow policymakers to directly gauge how climate change will impact societyand how society could alter the trajectory of climate change. For example, the model could predict how climate change will affect agriculture and migration patterns in Braziland also how cuts in ethanol subsidies might limit deforestation in the Amazon. Currently, climate scientists extract regional results from global climate models and pass them to experts in agriculture or economics to understand effects on human behavior. Now, says Erin Coughlan de Perez, a climate hazard scientist at the Red Cross Red Crescent Climate Centre, modelers are moving from just forecasting what weather will be, to what the weather will do.

Getting there wont be easy. Exascale supercomputers rely on both traditional computer chips as well as graphical processing units (GPUs), which are efficient at handling intensive calculations. GPUs are good for running model components in parallel and training artificial intelligence algorithmstwo techniques Destination Earth will lean on to enhance performance. But old climate modeling code will have to be reworked. ECMWF has a head start: It is adapting its forecast model to a GPU-based environment, and last year tested it at 1-kilometer resolution for 4 simulated months on Summit, the U.S. supercomputer that was the worlds fastest until a Japanese machine recently eclipsed it.

The massive amount of data generated by the model will be a problem of its own. When the Japanese team ran its 1-kilometer-scale experiment, it took half a year to extract something useful from a couple days of data, Doblas-Reyes says. Theres a bottleneck when we try to access the data and do something clever with it. A big part of Destination Earth will be solving this problem, designing ways to analyze model results in real time.

As an operational system, Destination Earth will likely run at several time scales, Bauer says. One will be near daily, perhaps targeting individual extreme weather events weeks or months in the future. Runs in the other modelong-term predictionswould be less frequent: perhaps a decadelong prediction of the climate made every half-year or so. If this works, it could be a template for other countries to follow, Bauer says.

The Europeans arent alone in planning for exascale climate models. Were heading in that direction as well, but weve yet to reach that level of effort, says Leung, who serves as chief scientist for DOEs earth system model.

Stevens says its thrilling to be involved in a truly planetary-scale information system that can reveal not just the proverbial butterfly effect in weather and climate, but also how local human actions manifest globally. Thats the story of globalization. Thats the story of the Anthropocene. And this is the scientific platform that will allow you to explore those.

Read the original here:
Europe is building a 'digital twin' of Earth to revolutionize climate forecasts - Science Magazine